Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932362 | 0.90 | LRRK2 (0.57) | PIM3LRRK2CA12CA1CA2 | |
| SCHEMBL2929139 | 0.82 | AKR1C3 (0.46) | PIM3HPGDLRRK2MAPTMEN1 | |
| SCHEMBL2933640 | 0.82 | CDK2 (0.48) | PIM3LRRK2MAPTMEN1KMT2A | |
| SCHEMBL2928592 | 0.82 | PIM3 (0.71) | PIM3HPGDCSNK2A1 | |
| SCHEMBL2936464 | 0.78 | LRRK2 (0.47) | PIM3HPGDLRRK2MEN1KMT2A | |
| SCHEMBL2925792 | 0.77 | PIM3 (0.55) | PIM3HPGDMAPTMEN1KMT2A | |
| SCHEMBL2932811 | 0.76 | CDK2 (0.66) | PIM3MAPTKMT2AMAPK1GAA | |
| SCHEMBL6657536 | 0.73 | HCAR3 (0.55) | CDK2 | |
| SCHEMBL7147442 | 0.73 | CDC25B (0.63) | HPGDCA12CA1CA2CA4 | |
| SCHEMBL2217939 | 0.72 | CA12 (0.65) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PIM3 2131/4885HPGD 3066/4885LRRK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.